Risk-Based Approach for Defining Retest Dates for Active Pharmaceutical Ingredients and Excipients

被引:0
|
作者
Charoo, Naseem A. [1 ]
Akanji, Omotayo [2 ]
Rahman, Ziyaur [3 ]
Khan, Aqeel A. [4 ]
Badshah, Aqal [4 ]
机构
[1] Aramed, 216 Lab Complex,Dubai Sci Pk,POB 478861, Dubai, U Arab Emirates
[2] Katchey Labs, 26 Adeniyi,Adeniyi Jones Ave, Ogba 101233, Ikeja, Nigeria
[3] Texas A&M Univ, Irma Lerma Rangel Coll Pharm, Texas A&M Hlth Sci Ctr, College Stn, TX 77843 USA
[4] Adcan Pharma LLC, ICAD, POB 9824, Abu Dhabi, U Arab Emirates
关键词
retest; risk assessment; critical material attributes; critical quality attributes; shelf life; PARTICLE-SIZE; QUALITY; SEGREGATION; FORMS; FLOWABILITY; STABILITY; BEHAVIOR; DESIGN; IMPACT; MODEL;
D O I
10.3390/ph17070903
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug substances and excipients must be stored in recommended storage conditions and should comply with their specifications during the retest period for their use in the manufacture of drug products. The ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) and WHO (World Health Organization) regulatory guidelines mandate that after the retest period, the drug substances must be retested for compliance with the specification and then used immediately in the manufacture of the finished product. Although these substances can be retested multiple times, an emphasis is placed on immediate use following a retest and compliance with standards. The phrase "used immediately" is ambiguous and is left for interpretation. In this article, we will look at the various processes that must be completed to determine the retest date. In addition, we present a risk-based method for establishing retest dates and the time during which material can be used.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Silica based metal scavengers for the purification of pharmaceutical active ingredients
    Beland, Francois
    Michaud, Annie
    Morin, Michel
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 722 - 722
  • [32] Defining Operational Design Domain for Autonomous Systems: A Domain-Agnostic and Risk-Based Approach
    Adedjouma, Morayo
    Botella, Bernard
    Ibanez-Guzman, Javier
    Mantissa, Kevin
    Proum, Chauk-Mean
    Smaoui, Asma
    2024 19TH ANNUAL SYSTEM OF SYSTEMS ENGINEERING CONFERENCE, SOSE 2024, 2024, : 166 - 171
  • [33] Active pharmaceutical ingredients based on salicylate ionic liquids: insights into the evaluation of pharmaceutical profiles
    Pinto, Paula C. A. G.
    Ribeiro, Diogo M. G. P.
    Azevedo, Ana M. O.
    Dela Justina, Vanessa
    Cunha, E.
    Bica, K.
    Vasiloiu, M.
    Reis, Salette
    Saraiva, M. Lucia M. F. S.
    NEW JOURNAL OF CHEMISTRY, 2013, 37 (12) : 4095 - 4102
  • [34] A flexible active distribution system expansion planning model: A risk-based approach
    Moradijoz, M.
    Moghaddam, M. Parsa
    Haghifam, M. R.
    ENERGY, 2018, 145 : 442 - 457
  • [35] Practical analysis and background information in the pharmaceutical daily routine/Active ingredients and excipients - identical certificates of analysis, but a different performance
    Tawab, Mona
    PHARMAZEUTISCHE INDUSTRIE, 2011, 73 (06): : 1120 - +
  • [36] Tanker inspection and a risk-based approach
    Ma, K
    PROCEEDINGS OF THE EIGHTH INTERNATIONAL OFFSHORE AND POLAR ENGINEERING CONFERENCE, VOL 4, 1998, : 504 - 512
  • [37] A Risk-Based Approach to Penicillin Allergy
    Trubiano, Jason A.
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2022, 42 (02) : 375 - 389
  • [38] The risk-based approach to Polar Code
    不详
    NAVAL ARCHITECT, 2011, : 32 - +
  • [39] A Risk-Based Approach to Deviation Management
    Bredehoeft, Gail
    O'Hara, Judy
    BIOPHARM INTERNATIONAL, 2009, 22 (04) : 48 - +
  • [40] A risk-based approach for a national assessment
    Whelan, G
    Laniak, GF
    RISK-BASED CORRECTIVE ACTION AND BROWNFIELDS RESTORATIONS, 1998, (82): : 55 - 74